DDInter79 DDInter704
Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers. Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure. The option for single daily dosing of amlodipine is an attractive feature of this drug [FDA label].
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Amlodipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Amlodipine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Amlodipine {u} (Compound) upregulates {v} (Gene) INSIG1
INSIG1 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Amlodipine {u} (Compound) downregulates {v} (Gene) EZH2
EZH2 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Amlodipine {u} (Compound) downregulates {v} (Gene) RPIA
RPIA {u} (Gene) is downregulated by {v} (Compound) Everolimus
Amlodipine {u} (Compound) upregulates {v} (Gene) GNPDA1
GNPDA1 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Amlodipine {u} (Compound) causes {v} (Side Effect) Gastritis
Gastritis {u} (Side Effect) is caused by {v} (Compound) Everolimus
Amlodipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Amlodipine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Amlodipine {u} (Compound) upregulates {v} (Gene) INSIG1
INSIG1 {u} (Gene) is regulated by {v} (Gene) CREG1
CREG1 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Amlodipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound)
Amlodipine (Compound) upregulates INSIG1 (Gene) and INSIG1 (Gene) is upregulated by Everolimus (Compound)
Amlodipine (Compound) downregulates EZH2 (Gene) and EZH2 (Gene) is upregulated by Everolimus (Compound)
Amlodipine (Compound) downregulates RPIA (Gene) and RPIA (Gene) is downregulated by Everolimus (Compound)
Amlodipine (Compound) upregulates GNPDA1 (Gene) and GNPDA1 (Gene) is downregulated by Everolimus (Compound)
Amlodipine (Compound) causes Gastritis (Side Effect) and Gastritis (Side Effect) is caused by Everolimus (Compound)
Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)
Amlodipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)
Amlodipine (Compound) upregulates INSIG1 (Gene) and INSIG1 (Gene) is regulated by CREG1 (Gene) and CREG1 (Gene) is upregulated by Everolimus (Compound)